Exercise as a cancer ally: could a bike ride supercharge immunotherapy?
NCT ID NCT07786909
First seen Aug 26, 2026 · Last updated Aug 27, 2026 · Updated 1 time
Summary
This trial tests whether a structured exercise program can strengthen the immune system's attack on non-small cell lung cancer. Patients receiving chemo-immunotherapy before surgery will either follow an exercise plan with a stationary bike or receive standard recommendations. The study measures if exercise increases cancer-fighting immune cells inside the tumor, potentially making treatment more effective.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- A structured exercise program (using an exercise bike and heart rate monitor) during neoadjuvant chemo-immunotherapy
- What this could lead to
- If exercise boosts immune cells in the tumor, it could make chemo-immunotherapy more effective for lung cancer patients, potentially improving outcomes without extra drugs.
- What could go wrong
- This is a small, early-phase pilot study. The exercise program may not significantly change the tumor's immune environment, and results may not apply to all patients. Adherence to the exercise regimen could also be challenging.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 40 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jul 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Patients with locally advanced, resectable non-small cell lung cancer (NSCLC), stage IIA (≥ 4 cm) to IIIA according to the TNM classification (American Joint Committee on Cancer, 9th edition) * PD-L1 positive * ECOG performance status of 0 or 1 at diagnosis * Sufficient tumor material for the analyses planned by the study Note: The amount of available material must be validated by the coordinating center before patient enrollment * With measurable disease according to RECIST version 1.1 criteria * Recently diagnosed and eligible for neoadjuvant chemotherapy-immunotherapy, as decided by the multidisciplinary tumor board (MTB) * Having obtained medical certification of fitness to engage in physical activity, issued by the referring oncologist or the principal investigator * Willing and deemed likely to comply with the intervention and visit schedule and follow-up examinations throughout the duration of the study * Able to understand, read, and speak French * Affiliated with a social security scheme * Having been informed about the study and having signed an informed consent form Exclusion Criteria: * Activating EGFR mutations or ALK translocations, as well as those who have received prior chemotherapy, immunotherapy, or radiotherapy for their current lung cancer * History of cancer within the last 5 years * Uncontrolled cardiovascular disease, including heart failure, unstable coronary artery disease, severe arrhythmias, or uncontrolled hypertension that could limit participation in physical activity, according to the investigator * Uncontrolled type 2 diabetes despite appropriate treatment * Severe limiting pulmonary disease such as GOLD stage IV chronic obstructive pulmonary disease, or severe restrictive lung disease * Major neuropsychiatric disorders that could hinder participation in the program (e.g., dementia, Alzheimer's disease, advanced Parkinson's disease) * Severe physical disability or any other medical condition that contraindicates participation in an exercise program • Concurrent participation in another physical activity study * Pregnant woman * Person deprived of liberty by judicial or administrative decision, or adult protected by law
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Lung neoplasms are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Centre Léon Berard (CLB)
Lyon, Rhône, 69373, France
-
Hopitaux Nord Ouest
Villefranche-sur-Saône, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug shrink advanced solid tumors?
- Can a targeted drug delivery system shrink lung tumors?
- Can a new drug shrink tumors that resist standard care?
- Can a Three-Dose immunotherapy cure early lung cancer without surgery?
- Can a new drug shrink advanced solid tumors?
- Can a less extensive lung cancer surgery be just as effective?